Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: Costs, methods and applications

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 7, 2011, Pages 1105-1111

  Di Francia, Raffaele ^a   Berretta, Massimiliano ^b   Catapano, Oriana ^c   Canzoniero, Lorella M T ^d   Formisano, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c Italian Association of Pharmacogenomics and Molecular Diagnostics   (Italy)

^d UNIVERSITY OF SANNIO   (Italy)

Author keywords

5 FU; genotyping cost; molecular diagnostics; polymorphism detection methods

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROPYRIMIDINE DEHYDROGENASE 2A; DNA; FLUOROPYRIMIDINE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; ISOPROTEIN; LOCKED NUCLEIC ACID; MESSENGER RNA; OXALIPLATIN; PEPTIDE NUCLEIC ACID; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ALLELE; ALLELE SPECIFIC AMPLIFICATION; COLORECTAL CANCER; DENATURING GRADIENT GEL ELECTROPHORESIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA POLYMORPHISM; DRUG DETERMINATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; GERMLINE MICRONUCLEUS; GOLD STANDARD; HEALTH CARE COST; HETERODUPLEX DNA ASSAY; HIGH RESOLUTION MELTING ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; LEUKOPENIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROANALYSIS; MOLECULAR DIAGNOSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PEPTIDE NUCLEIC ACID MEDIATED CLAMPING; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PYROSEQUENCING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL; TUMOR CELL; VOMITING; WILD TYPE;

ENZYMES; FLUOROURACIL; GENETIC VARIATION; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS;

EID: 79960264333     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.181     Document Type: Review

References (41)

1. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and non-genetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8
2. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55
3. Camilleri M, Saito YA. Pharmacogenomics in gastrointestinal disorders. Methods Mol Biol 2008;448:395-412
4. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14:1059-64 (Pubitemid 351302551)
5. Balboa E, Duran G, Lamas MJ, Gomez-Caamano A, Celeiro- Munoz C, Lopez R, et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 2010;11:747-61
6. Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 2010;11:643-6
7. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-67
8. Dhalla IA, Garner S, Chalkidou K, Littlejohns P. Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care 2009;25:272-80
9. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006;27:432-7 (Pubitemid 44051569)
10. Zhang H, Li YM, Zhang H, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007;24:251-8 (Pubitemid 350135979)
11. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009;100:1549-57
12. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14: 319-27 (Pubitemid 38638919)
13. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010;69:58-66
14. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54 (Pubitemid 46640571)
15. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez- Salguero P, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51:391-400 (Pubitemid 28413205)
16. Ogura K. wDihydropyrimidine dehydrogenase activity and its genetic aberrationsx. Gan To Kagaku Ryoho 2006;33:1041-8
17. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007;43: 1011-6 (Pubitemid 46483039)
18. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007;60: 503-7 (Pubitemid 47084259)
19. Okamoto Y, Ueta A, Sumi S, Ito T, Okubo Y, Jose Y, et al. SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit. Biochem Genet 2007;45:713-24 (Pubitemid 47630625)
20. Morel A, Boisdron-Celle M, Fey L, Laine-Cessac P, Gamelin E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007;40:11-7 (Pubitemid 46014150)
21. Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD IVS14q1G)A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther 2007;11:105-8 (Pubitemid 46572571)
22. Yawata A, Kim SR, Miyajima A, Kubo T, Ishida S, Saito Y, et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother Pharmacol 2005;56:465-72 (Pubitemid 41549147)
23. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil- based chemotherapy. Clin Cancer Res 2004;10:5880-8 (Pubitemid 39180969)
24. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70 (Pubitemid 33757985)
25. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-30 (Pubitemid 33010548)
26. Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006;24: 4062-8 (Pubitemid 46628475)
27. Acuna M, Eaton L, Cifuentes L, Massardo D. Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population. Br J Clin Pharmacol 2006;61:778-82 (Pubitemid 43794810)
28. Xu WH, Long JR, Zheng W, Ruan ZX, Cai Q, Cheng JR, et al. Association of thymidylate synthase gene with endometrial cancer risk in a Chinese population. Cancer Epidemiol Biomarkers Prev 2009;18:579-84
29. Meyer K, Fredriksen A, Ueland PM. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators. Clin Chem 2009;55: 139-49
30. Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst 2006;98: 1607-22 (Pubitemid 44811644)
31. Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, Gonzalez-Aguilera JJ. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis 2010;25:141-51
32. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatinbased chemotherapy. Clin Cancer Res 2006;12:3050-6 (Pubitemid 43837350)
33. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000;86:1-7 (Pubitemid 30133979)
34. Georgiadis P, Demopoulos NA, Topinka J, Stephanou G, Stoikidou M, Bekyrou M, et al. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicol Lett 2004;149:269-80 (Pubitemid 38469845)
35. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010;28:3227-33
36. Fontana L, Delort L, Joumard L, Rabiau N, Bosviel R, Satih S, et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res. 2009; 29: 1631-5.
37. Norambuena PA, Copeland JA, Krenkova P, Stambergova A, Macek M Jr. Diagnostic method validation: high resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Clin Biochem 2009; 42:1308-16
38. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004; 24:720-6 (Pubitemid 38747856)
39. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006;7:783-92 (Pubitemid 44225913)
40. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009;115:3858-67
41. Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med 2007;356:1094-7 (Pubitemid 46425594)